Galapagos NV(NASDAQ:GLPG) 
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ul...
Website: http://www.glpg.com
Founded: 1999
Full Time Employees: 1,407
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 23.95
H 24.06
L 23.38
C 23.75
V 278,950
10EMA 23.75
20EMA 23.75
60EMA 23.75
120EMA 23.75
250EMA 23.75